Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab.

ABSTRACT:

Background

Atezolizumab plus bevacizumab (Ate/Bev) is the first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). However, the prognostic impact of immune-related thyroid adverse events (irTAEs), particularly non-thyroidal illness syndrome (NTIS), remains unclear.

Methods

We retrospectively analyzed 70 patients with unresectable HCC treated with Ate/Bev. Thyroid function was monitored at baseline and during the treatment. IrTAEs were classified as NTIS (low T3 and/or free T4 with normal or low TSH levels) or thyroid adverse events (hypothyroidism or thyrotoxicosis). Clinical outcomes, including progression-free survival (PFS) and overall survival (OS), were assessed using Kaplan-Meier and Cox regression analysis. Subgroup analyses were performed to exami

SUBMITTER: Chen IW 

PROVIDER: S-EPMC12847513 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature